Trial · NCT07894263
2D:4D Ratio vs Semen Parameters
NCT07894263, Completed, Suleyman Demirel University
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. 2D:4D Ratio vs Semen Parameters. Trials, record NCT07894263. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07894263
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- 2D:4D Ratio vs Semen Parameters
- NCT number
- NCT07894263
- Status
- Completed
- Enrollment
- 22 participants, actual
- Lead sponsor
- Suleyman Demirel University
- Conditions
- Male
- Interventions
- Group 1
- First posted
- 2026-10-26
- Last updated
- 2026-10-26
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Hand and finger lengths (2d:4d) | Baseline (Day 0) | Measurements were taken using standardized digital palm photographs taken with the hand placed on a metric surface at a height of 50 cm. The images were analyzed using ImageJ v1.50 software according to international anthropometric protocols (ISAK, WHO, NASA, and the Anthropometric Standardization Reference Guide). Hand length (HL - distance from the wrist crease at the radiocarpal joint to the distal tip of the third finger), hand width (HW - maximum distance between the second and fifth metacarpal heads), wrist width (WW - distance between the radial and ulnar styloid processes), 2D (distance from the metacarpophalangeal crease of the index finger to the fingertip), and 4D (distance from the metacarpophalangeal crease of the ring finger to the fingertip) were measured. The 2D:4D ratio was calculated by dividing the length of the second finger by the length of the fourth finger. |
| Primary | Semen analysis | Baseline (Day 0) | Semen samples were collected by masturbation after 2-7 days of sexual abstinence using sterile containers and allowed to liquefy for 30 minutes at 37°C. Ejaculate volume (EjVol) was measured in mL by direct volume assessment and classified as hypospermia (\<1.5 mL), normo-volume (1.5-5 mL), or hyperspermia (\>5 mL). Sperm concentration (SC) was calculated as total sperm count/semen volume and categorized as severe oligozoospermia (\<5 million/mL), mild-moderate oligozoospermia (5-15 million/mL), normozoospermia (15-200 million/mL), or polyspermia (\>200 million/mL).Total motility (ABC) was defined as the percentage of progressive (A+B) and non-progressive (C) motile sperm and classified as severe asthenozoospermia (\<20%), moderate motility impairment (20-39%), borderline normal motility (40-60%), and good motility (\>60%). Progressive motility (PM) was evaluated as severe (\<10%), reduced (10-31%), normal (32-50%), or good (\>50%). |
| Primary | Hormone analysis | Baseline (Day 0) | Hormone levels were measured by Enzyme-Linked Immunosorbent Assay (ELISA) from fasting venous serum samples, and the relationships between hand/finger lengths and ratios were evaluated.Hormonal evaluation included the examination of folic acid (FA), follicle-stimulating hormone (FSH), luteinizing hormone (LH), prolactin (PRL), and total testosterone (TT) levels. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07894263
GET https://conductscience.org/api/trials/v1/NCT07894263/registered